Physician profile
Sherry Gates
NPI 1518678069
$682.06
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $252 · 2024: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $682.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $167.08 | 2023-2024 | Lokelma, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $66.25 | 2023-2024 | Gattex |
| Otsuka America Pharmaceutical, INC. | $57.26 | 2023-2024 | Jynarque |
| Amgen INC. | $56.08 | 2023-2024 | Parsabiv, Tavneos, Aranesp |
| Glaxosmithkline, LLC. | $54.43 | 2023-2024 | Benlysta, Jesduvroq |
| Calliditas Therapeutics US INC. | $48.99 | 2023-2024 | Tarpeyo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $43.53 | 2024 | |
| Baxter Healthcare | $37.02 | 2024 | Renal - Chronic |
| Travere Therapeutics, INC. | $29.18 | 2023 | |
| Kyowa Kirin, INC. | $27.60 | 2024 | Crysvita |
| Ardelyx, INC. | $21.50 | 2024 | Ibsrela |
| Biomerieux INC | $21.00 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.58 | 2023 | |
| Vifor Pharma, INC. | $17.69 | 2023 | Veltassa |
| Opko Pharmaceuticals, LLC | $15.87 | 2024 | Rayaldee |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Gates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.